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Precise diagnosis of interstitial lung diseases, with mul-
tidisciplinary discussion (MDD) being a key element, is
gaining importance in daily practice as novel antifibrotic
therapies for idiopathic pulmonary fibrosis are emerging.
We assessed the diagnostic impact of MDD in a real life
setting by retrospective analysis. With a change or adjust-
ment of diagnosis in 64% (overall diagnostic consensus
in 88%), we support results of previously conducted con-
trolled studies by reflection of our daily clinical routine.
Introduction and background
Interstitial lung diseases (ILDs) represent a variety of lung
parenchymal disorders that are difficult to diagnose and
distinguish in their specific subtypes. Since January 2016,
two antifibrotic medications have become available for the
treatment of patients with idiopathic pulmonary fibrosis
(IPF) in Switzerland. This makes it even more crucial to
distinguish IPF from other ILDs. MDD has been proven to
increase consensus diagnosis among specialists involved in
ILD patient care and to avoid further invasive investiga-
tions [1]. MDD has so far not been evaluated in daily clin-
ical routine, outside a study protocol.
Methods and results
We retrospectively evaluated MDD as diagnostic approach
in patients referred to our tertiary ILD clinic over 2 years.
The patients’ cases were presented to the MDD either by
their referring doctor or by internal pulmonologists, who
had a consultation with the patient first and proposed a
provisional ILD diagnosis. An extended patient history,
physiological assessment (including pulmonary function
tests, serology) and chest computed tomography (CT) scan
were always available beforehand. If patients were suit-
able, bronchoscopy with bronchoalveolar lavage and trans-
bronchial biopsy, and if necessary surgical lung biopsy,
were performed before MDD, according to the initial es-
timation of the treating pulmonologist. Clinicians, radiolo-
gist and pathologist discussed the cases together in a com-
mon session, expressed their opinions on the specific ILD
diagnosis, and had the possibility to change their initial
diagnosis taking into account the findings and judgment
of their colleagues. Diagnostic consensus was defined as
agreement on diagnosis of all participating specialists.
We retrospectively evaluated the specific ILD diagnosis be-
fore and after MDD.
During 24 months a total of 90 cases were discussed. Pa-
tients were predominantly male (55/90, 61%) with an aver-
age age of 61.5 years (men 63.5 years; women 58.5 years).
Fifty-six percent (50/90) of cases were referred by pul-
monologists in private practice, 23% (21/90) by general
practitioners and 21% (19/90) were internal referrals from
inside our hospital. In addition to clinical evaluation and
chest CT scan, pathological results were available in 74%
(67/90) of cases. A total of 33/90 (36%) patients underwent
transbronchial biopsy, of which 5 were diagnostic (15%);
39/90 (43%) patients had surgical biopsy, resulting in a his-
tological diagnosis in 34/39 (87%) cases. Bronchoalveolar
lavage was performed in 49/90 (54%) cases.
Overall, MDD achieved a precise diagnosis in 79/90 pa-
tients (88%), and the diagnosis was changed in 58/90
(64%) cases after MDD (figure). In 10 cases (11%) the sus-
pected diagnosis was rejected and an alternative diagnos-
is was suggested. In total, 16 (18%) of the cases could not
be assigned a confident diagnosis, with 5 already having
a contributory biopsy (definitely unclassifiable) and the re-
maining 11 (12%) being provisionally unclassifiable, indic-
ating that additional diagnostic steps could possibly lead to
diagnosis. Interestingly, in patients with initially suspected
IPF, IPF not always proved to be the final diagnosis: It was
confirmed in 64%, but in 36% the diagnosis was rejected
after MDD. In several of these cases (14%) nonspecific in-
terstitial pneumonia was the final diagnosis instead.
Discussion and conclusion
We report on our real-life experience of MDD in our Swiss
ILD centre. MDD provided a precise diagnosis in the ma-
jority of cases (88%). Diagnosis needed to be corrected in
64% by MDD (fig.).
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In oncology, multidisciplinary boards are widely applied
and have demonstrated a significant impact on treatment
decisions through collaboration between specialists [2].
IPF, a devastating disease, shows similarities with cancer:
both diseases respond poorly to medical therapy, with IPF
having a lower 5-year survival rate than many malignant
neoplasms (e.g. colon, breast, kidney) [3]. Genetic changes
and signalling pathways that are targets for new therapies
(e.g. tyrosine kinase inhibitors) are overlapping [4]. Fur-
thermore, as with cancer, decision making about diagnostic
steps, final diagnosis and treatment benefits from the opin-
ion of different specialists. This emphasises the role of
MDD as an obvious approach. Nevertheless, MDD is not
routinely used for all ILD patients.
The 2013 updated guidelines of the American Thoracic
Society and the European Respiratory Society on classi-
fication of idiopathic interstitial pneumonias [5] strongly
recommend the dynamic interaction and information ex-
change between clinicians, radiologists and pathologists in
the diagnostic process of suspected ILD. MDD can be con-
sidered as the diagnostic gold standard in ILD manage-
ment today. The combination of clinical with histological
information is an asset for diagnosis [6]. MDD increased
diagnostic confidence and agreement between specialists in
a study setting where information was presented in portions
in a strict stepwise protocol to the board members [1].
Here we report our real-life experience in diagnosing ILDs
at our tertiary centre and confirm the efficacy of MDD in
a daily setting. We are aware that this retrospective obser-
vation carries bias and confounders, but we believe it to
add to the information from the previous controlled study
[1] and case based reviews [7] with a reflection of clinical
routine and daily practice in a real-life scenario [8].
Current guidelines on diagnosis of IPF [9] suggest that
MDD should include surgical lung biopsy that has been
obtained beforehand; however, guidelines on diagnosis of
idiopathic interstitial pneumonias [5] state that MDD
should be used to discuss if lung biopsy is even appropri-
ate. Depending on the question asked, the treating clinician
decides about the time-point of MDD. After MDD the ma-
jority of cases could be labelled with one of the diverse
specific ILD subtypes including the entity of unclassifiable
ILD (fig.). Eleven “unresolved” cases (12%) were labelled
Figure
Diagnosis (Dx) before and after multidisciplinary discussion (MDD)
for interstitial lung disease (ILD).
IPF = idiopathic pulmonary fibrosis; NSIP = nonspecific interstitial
pneumonia; HP = hypersensitivity pneumonitis; OP = organising
pneumonia.
Other diagnosis (1–2 cases each) included: combined pulmonary
fibrosis and emphysema, Langerhans cell histiocytosis, vasculitis,
respiratory bronchiolitis ILD, pulmonary lymphangioleiomyomatosis,
Birt-Hogg-Dubé syndrome and diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia.
as provisionally unclassifiable without a lung biopsy (e.g.
not eligible for surgery) and theoretically another specif-
ic ILD might have been determined. Our clinical experi-
ence corresponds to a recent review [10] that defined the
term “provisional” unclassifiable ILD and reported that
5.1–15.1% of all ILD cases remain unclassifiable.
Correct ILD diagnosis is of utmost importance since it
entails different treatment options: immunosuppressive
agents can be indicated for patients with non-IPF ILDs but
can increase morbidity and mortality in IPF patients [11]
for whom novel cost-intensive antifibrotic treatments are
now available [4, 12]. We assume this paradigm shift has
reignited diagnostic interest in IPF all over the medical
community, reflected in the 24% of our cases referred with
the specific suspicion of IPF.
In conclusion, by describing the diagnostic impact of our
MDD integrated in clinical ILD routine we observed an ad-
justment in diagnosis in 64% and an overall diagnostic con-
sensus in 88% of the discussed cases. It is crucial to identi-
fy patients with reversible ILDs [13] and distinguish them
from IPF, to determine the moment of intervention and be-
ginning of therapy, and to arrange accurate long-term mon-
itoring. By demonstrating the pivotal role of MDD in the
diagnosis of suspected ILD in real life we want to high-
light the importance of early multidisciplinary assessment,
which improves diagnostic precision.
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Figures (large format)
Figure
Diagnosis (Dx) before and after multidisciplinary discussion (MDD) for interstitial lung disease (ILD).
IPF = idiopathic pulmonary fibrosis; NSIP = nonspecific interstitial pneumonia; HP = hypersensitivity pneumonitis; OP = organising pneumonia.
Other diagnosis (1–2 cases each) included: combined pulmonary fibrosis and emphysema, Langerhans cell histiocytosis, vasculitis, respiratory
bronchiolitis ILD, pulmonary lymphangioleiomyomatosis, Birt-Hogg-Dubé syndrome and diffuse idiopathic pulmonary neuroendocrine cell
hyperplasia.
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